stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Debt to equity
ImmunityBio, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was −0.7×, up 0.2× from fiscal 2025 (−1.0×). Over the past ten years it has ranged from −2.5× (fiscal 2021) to 0.1× (fiscal 2019); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −1.0× | — |
| FY2024 | −0.9× | — |
| FY2023 | −1.2× | — |
| FY2022 | −1.5× | — |
| FY2021 | −2.5× | — |
| FY2020 | −2.2× | — |
| FY2019 | 0.1× | 160.04% |
| FY2018 | 0.0× | 337.96% |
| FY2017 | 0.0× | 24.14% |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | −0.7× | — |
| Mar 2026 | −0.8× | — |
| Dec 2025 | −1.0× | — |
| Sep 2025 | −1.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| IBRX ImmunityBio, Inc. | −0.7× |
| CYTK Cytokinetics, Incorporated compare | −0.5× |
| KRYS Krystal Biotech, Inc. compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| SYRE Spyre Therapeutics, Inc. compare | 0.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 0.0× |
| TWST Twist Bioscience Corporation compare | 0.0× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.5× |
| TGTX TG Therapeutics, Inc. compare | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement